SAB Biotherapeutics (NASDAQ:SABS) Trading Up 0.6% – Time to Buy?

SAB Biotherapeutics, Inc. (NASDAQ:SABS)’s share price was up 0.6% during trading on Wednesday . The stock traded as high as $3.67 and last traded at $3.62. Approximately 368,862 shares were traded during trading, a decline of 56% from the average daily volume of 835,619 shares. The stock had previously closed at $3.60.

Analysts Set New Price Targets

A number of brokerages recently weighed in on SABS. Barclays assumed coverage on shares of SAB Biotherapeutics in a research note on Wednesday, June 24th. They issued an “overweight” rating and a $13.00 target price on the stock. Leerink Partners increased their price target on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, June 15th. Weiss Ratings restated a “sell (d+)” rating on shares of SAB Biotherapeutics in a research report on Wednesday, July 8th. Zacks Research raised shares of SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Finally, Chardan Capital boosted their target price on SAB Biotherapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Wednesday, June 17th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $12.00.

SAB Biotherapeutics Price Performance

The firm has a fifty day moving average of $3.72 and a two-hundred day moving average of $3.85. The company has a current ratio of 11.45, a quick ratio of 11.45 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $275.26 million, a PE ratio of -1.71 and a beta of 0.52.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.15). Research analysts anticipate that SAB Biotherapeutics, Inc. will post -1.19 EPS for the current fiscal year.

Institutional Trading of SAB Biotherapeutics

Several large investors have recently modified their holdings of SABS. Vivo Capital LLC bought a new stake in SAB Biotherapeutics in the third quarter valued at $22,954,000. Perceptive Advisors LLC lifted its position in SAB Biotherapeutics by 700.8% during the 1st quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock valued at $24,634,000 after acquiring an additional 5,628,533 shares during the period. RA Capital Management L.P. bought a new stake in SAB Biotherapeutics during the third quarter worth about $8,847,000. Woodline Partners LP purchased a new stake in SAB Biotherapeutics in the third quarter worth about $5,730,000. Finally, Spruce Street Capital LP purchased a new stake in SAB Biotherapeutics in the fourth quarter worth about $8,222,000. 7.82% of the stock is owned by institutional investors.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.